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Abstract The purpose of the paper was to assess the
effects of oral contraceptives on selected parameters of the
homeostatic control system in women having a sudden
disorder of the auditory and/or balance system. The study
included 105 young women divided into two groups:
Group I—52 women with the disorder of the auditory and/
or balance system using hormonal contraceptives for at
least 2 months, aged 20–49; and Group II—53 women
without any disorder of the auditory and/or balance system
using hormonal contraceptives for at least 2 months, aged
18–40. The patients included in the study underwent a full
otoneurological evaluation, detailed laryngological diag-
nostics and an evaluation of selected parameters of the
homeostatic control system—fibrinogen level, D-dimer
level, evaluation of APTT and PT indicator, plasma
estradiol and progesterone with the Roche Cobas analyser
by means of chemiluminescence. The vertigo occurring in
the study group was most often central (59.6 % of cases),
mixed with compensation in 36.6 % of cases, and periph-
eral only in 3.8 % of cases, indicating labyrinth damage in
40.4 % of cases. An analysis of the progesterone level,
considering the menstrual cycle phase in the group, showed
that its value was abnormal in 51.0 % of women in the
study group and 47.1 % in the control group. In their own
studies, the authors observed that the estradiol level in the
plasma, considering the menstrual cycle phase in the study
group, was abnormal in 41.2 % of women and that the
differences in its concentration were statistically significant
in the study and control groups (p = 0.005), which may
have a negative impact on the possibility of a thrombo-
embolic episode.
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Introduction
Since the 1960s oral contraceptives have been a well-
known risk factor for thromboembolic episodes. Studies
indicate that in women taking contraceptives the risk of
venous thrombosis increases by 3–6 times. The conve-
nience and reliability of this contraceptive method are the
reasons why the pharmaceutical industry continues to
improve it and performs research on new agents.
The most common reason for the discontinuation of
contraception by women is the occurrence or fear of
adverse effects. The most severe ones are thromboembolic
complications that may be a direct cause of death. The
most severe conditions that are directly life or health-
threatening to the patient include: myocardial infarction,
pulmonary embolism and cerebrovascular accident.
A theory was put forward to explain oestrogen/proges-
terone complex conditioning the risk of thrombus. The
joint action of these two hormones was said to have an
ultimate effect on coagulation and fibrinolysis. A decrease
in the estradiol dose reduced the risk of thromboembolic
complications, while the contraceptive effect was main-
tained. It was also confirmed that third-generation drugs
were considered to have a greater, total ‘‘oestrogen’’ effect,
and thus thrombus-promoting effect, than second-genera-
tion drugs [1–6].
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A thromboembolic episode is observed most frequently
during the first year, or even first 3 months, of taking
hormonal contraceptives. The most probable cause seems
to be the concurrence of a pre-existing genetic or envi-
ronmental factor with the additional factor of hormonal
contraception, leading to the pathological activation of the
coagulation system.
Currently, factors increasing the risk of thromboembolic
episodes by 2–5 times are considered strong. The genetic
factors of coagulation disorders include a deficit of natu-
rally occurring anticoagulant proteins, such as antithrom-
bin, protein C, protein S, and mutation of factor V Leiden
related to the resistance to the anticoagulative effect of
protein C. Additionally, it needs to be emphasised that
weak, accumulating hereditary risk factors of thrombo-
embolic disease increase the total risk of a disorder in the
coagulation system. They include having a blood type other
than O, certain genetic variants of prothrombin and
fibrinogen, and factor XIII or XI [7–9].
There are also mutations of proteins in the homeostatic
system, with anticoagulative effects and which decrease the
pro-coagulation properties.
Hormonal contraceptives increase the level of the fol-
lowing coagulation factors (Tables 1, 2): IX, X, XI, pro-
thrombin, and fibrinogen, while decreasing the level of
anticoagulative factors, e.g. antithrombin, proteins C and S,
thus disturbing the delicate balance and potentially leading
to thromboembolic disease [10, 12].
The purpose of the paper was to assess the effects of oral
contraceptives on selected parameters of the homeostatic
control system in young women with a sudden disorder of
the auditory and/or balance system.
Table 1 Biochemical and laboratory results in the study group
Statistical parameter
M SD SE 95 % CI Quartiles Min. Max.
Estradiol (pg/ml) 312.29 288.90 40.06 231.86–392.72 124.46;222.18;377.91 23.35 1,306.40
Follicular p. 404.09 306.26 74.64 248.88–559.31 145.79;236.77; 629.54 37.92 1,306.40
Ovulation peak 210.75 92.63 29.98 133.69–287.82 154.70;185.93; 276.60 139.15 322.22
Luteal p. 243.53 259.24 50.11 139.60–347.46 73.26; 226.60; 348.87 23.35 1,077.00
Progesterone (ng/ml) 3.28 3.51 0.49 2.30–4.25 0.80; 1.69; 5.00 0.29 15.00
Follicular p. 2.13 1.94 0.55 0.97–3.28 0.69; 1.13; 2.06 0.56 12.10
Ovulation peak 5.52 4.13 1.83 0.81–10.23 1.45; 5.28; 8.62 0.79 11.70
Luteal p. 3.88 3.12 0.78 2.26–5.51 0.79; 2.87; 6.60 0.29 15.00
D-dimers (lg/ml) 0.69 2.42 0.34 0.02–1.37 0.20; 0.31; 0.44 0.19 17.76
Fibrinogen (mg/dl) 245.12 67.03 9.30 226.45–263.78 208; 239.50; 278 89 395
APTT (s) 30.81 3.03 0.42 29.97–31.65 28.60; 30.55; 32.35 25.80 39.20
PT (s) 12.00 0.90 0.13 11.75–12.25 11.40; 11.80; 12.55 10.10 14.30
Table 2 Biochemical and laboratory results in the control group
Statistical parameter
M SD SE 95 % CI Quartiles Min. Max.
Estradiol (pg/ml) 214.81 256.76 35.27 144.04–285.58 64.03;106.68;218.20 23.35 1,012.90
Follicular p. 245.00 251.70 47.57 147.40–342.60 73.69;138.03;363.23 33.97 948.23
Ovulation peak 67.05 15.28 7.64 42.74–91.37 58.00; 72.84; 76.11 44.49 78.04
Luteal p. 202.70 282.92 61.74 73.92–331.48 39.04; 74.53; 203.98 23.35 1,012.90
Progesterone (ng/ml) 1.34 1.27 0.17 0.99–1.69 0.67; 0.87; 1.49 0.13 6.66
Follicular p. 1.24 1.10 0.21 0.81–1.67 0.75; 0.82; 1.30 0.34 6.05
Ovulation peak 0.86 0.33 0.16 0.34–1.38 0.61; 0.80; 1.11 0.55 1.29
Luteal p. 1.57 1.56 0.34 0.86–2.28 0.51; 1.27; 1.75 0.13 6.66
D-dimers (lg/ml) 0.36 0.45 0.06 0.23–0.48 0.19; 0.21; 0.34 0.19 3.39
Fibrinogen (mg/dl) 238.68 54.48 7.48 223.66–253.69 195; 231; 261 151 387
APTT (s) 29.78 2.10 0.29 29.20–30.35 28.40; 29.50; 31.30 24.60 34.00
PT (s) 12.06 0.63 0.09 11.88–12.23 11.60; 12.10; 12.60 10.80 13.40
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Materials and methods
The studies included 105 women hospitalised in the
Department of Otolaryngology and Laryngological
Oncology of the Military Medical Academy University
Teaching Hospital in Lodz, divided into two groups:
I—52 women with a disorder of the auditory and/or
balance system, using hormonal contraceptives for at least
2 months, aged 20–49 (mean age 33.31 ± 5.85 years),
II—53 women without the disorder of the auditory and/
or balance system, using hormonal contraceptives for at
least 2 months, aged 18–40 (mean age 29.13 ± 5.78 years).
The patients in the study underwent the following
procedures:
• Detailed otoneurological and gynaecological history,
especially with regard to: use of hormonal contraceptives,
duration of treatment, type of agent used, use of
anticoagulants, and concurrent liver diseases. The studies
did not include patients taking anticoagulants or those
with a history of thromboembolic disease. Any possible
liver diseases were excluded by laboratory tests.
• Physical laryngological and otoneurological
examination.
• Blood test (blood count, CRP, electrolytes, glucose
level and lipid profile) to exclude metabolic diseases;
hepatic enzyme assessment (ALAT, ASPAT) to
exclude liver diseases as a potential cause of homeo-
static disorders.
• Otoneurological diagnostics were performed, including
videonystagmography test (VNG), which included
recording of the spontaneous nystagmus, pendular
nystagmus, positional nystagmus, optokinetic nystag-
mus, kinetically induced nystagmus using the swivel
chair test and a neck torsion test.
• Audiometric examination, including: determination of
the noise level, tone threshold and suprathreshold
audiometry, speech audiometry, and brainstem evoked
response audiometry (BERA). In selected cases acous-
tic otoemission (TEOAE and DPOAE) and impedance
audiometry were performed: tympanometry and record-
ing of the stapedius reflex, with determination of the
reflex threshold at the frequencies of 500, 1,000, 2,000
and 4,000 Hz, with stimulation of the ipsi- and
contralateral pure tone and the Reflex Decay Test.
• Computer tomography or magnetic resonance of the
head to exclude any organic lesions.
• Doppler blood flow test in spinal arteries and the basilar
artery was performed with Tranpect-TCD, 2 MHz head
(entrance window—foramen magnum) and the neck
torsion test (to exclude vascular causes).
• Tests of selected parameters of the homeostatic system
(assessment of the fibrinogen level, D-dimer level,
assessment of the APTT and PT indicator), performed
by the Department of Laboratory Diagnostics and
Clinical Biochemistry of the Military Medical Acad-
emy University Teaching Hospital in Lodz, based on
the Sysmex CA-560 System by SIEMENS.
• Tests of the plasma estradiol and progesterone levels
performed at the Endocrinology Clinic of the Endocri-
nology Department of the Medical University of Lodz,
with the Roche Cobas analyser by means of chemilu-
minescence. The results for reproductive hormones
included differences in concentration depending on the
menstrual cycle.
Those women with a sudden auditory disorder were treated
with oral glucocorticoids, with the protective administra-
tion of proton pump inhibitors, vascular drugs and drugs
improving the metabolism of the cerebral tissue (in the
acute phase by intravenous drip, and orally after 5–7 days)
for approx. 30 days.
On the other hand, those women with sudden vertigo
were treated with antiemetic drugs only at the acute phase;
vascular drugs and drugs improving the metabolism of the
cerebral tissue, and blockers of the H3 autoreceptor.
The obtained results were subjected to statistical ana-
lysis using the following procedures (significance tests):
• Chen–Shapiro test (to estimate the normality of the
measurable variable distribution),
• Levene test (to estimate the equality of variances),
• Mann–Whitney–Wilcoxon rank sum test,
• v2 independence test,
• Fisher exact test,
• logistic regression.
The test results were considered statistically significant if
the significance level was p \ 0.05.
Results
In the study group (I), vertigo was: central in 31 (59.6 %)
patients (f = 0.5769); peripheral with compensation in 1
(1.9 %) patient (f = 0.0385); peripheral without compen-
sation in 1 (1.9 %) patient (f = 0.0192) and mixed with
compensation in 19 (36.6 %) patients (f = 0.3654). Thus,
labyrinth damage was diagnosed in 21 (40.4 %) patients in
the study group, including the right labyrinth in 12 patients
(23.1 %) and the left one in 9 patients (17.3 %).
On the other hand, auditory damage according to CPT
was 0.4–97.0 % (mean value 5.87 ± 16.69 %) for the right
ear, and from 0.1 to 53.0 % (mean value 3.47 ± 8.14 %)
for the left ear.
The tested estradiol level in the blood serum (pg/ml),
considering the menstrual cycle in the study group (I) was as
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follows: below normal in 6 (11.8 %) patients (f = 0.1176),
normal in 30 (58.8 %) patients (f = 0.5882) and above
normal in 15 (29.4 %) patients (f = 0.2941), whereas in the
control group (II), in 19 (35.8 %) patients (f = 0.3585), in 28
(52.8 %) patients (f = 0.5283) and in 6 (11.3 %) patients
(f = 0.1132), respectively. A statistical dependence of the
estradiol level in the blood serum between the study and
control group was found (p = 0.005).
The tested progesterone level in the blood serum (pg/
ml), considering the menstrual cycle in the study group
(I) was as follows: below normal in 12 (23.5 %) patients
(f = 0.2353), normal in 25 (49.0 %) patients (f = 0.4902)
and above normal in 14 (27.5 %) patients (f = 0.2745),
whereas in the control group (II), in 19 (35.8 %) patients
(f = 0.3585), in 28 (52.9 %) patients (f = 0.4717) and in 6
(11.3 %) patients (f = 0.1698), respectively. A statistical
dependence of the progesterone level in the blood serum
between the study and control group was not found.
The tested D-dimer level in the blood serum (lg/ml) in
the study group (I) was as follows: normal in 42 (80.8 %)
patients (f = 0.8077) and above normal in 10 (19.2 %)
patients (f = 0.1923), whereas in the control group (II) in
43 (81.1 %) patients (f = 0.8113) and above normal in 10
(18.9 %) patients (f = 0.1887), respectively. A statistical
dependence between the D-dimer level in the blood serum
in the study and control group was not found.
The fibrinogen level in the blood serum (mg/dl) in the
study group (I) was as follows: below normal in 10
(19.2 %) patients (f = 0.1923) and normal in 42 (80.8 %)
patients (f = 0.8077), whereas in the control group (II) in
14 (26.4 %) patients (f = 0.2642) and normal in 39
(73.6 %) patients (f = 0.7358), respectively. A statistical
dependence of the fibrinogen level in the blood serum
between the study and control group was not found.
The prothrombin time (s) tested in the study group (I) was
as follows: below normal in 45 (86.5 %) patients
(f = 0.8654) and normal in 7 (13.5 %) patients (f = 0.1346),
whereas in the control group (II) in 50 (94.3 %) patients
(f = 0.9434) and in 3 (5.7 %) patients (f = 0.0566),
respectively. A statistical dependence of the prothrombin
time in the blood serum between the study and control group
was not found. The tested APTT coagulation time was nor-
mal in all women in the study and control groups.
In the study group (I), the biochemical and laboratory
results were as follows (Table 1): mean serum estradiol—
312.29 ± 92.63 pg/ml, in the follicular phase—404.09 ±
306.26 pg/ml, in the ovulation peak—210.75 ± 288.90
pg/ml and in the luteal phase—243.53 ± 259.24 pg/ml;
mean blood progesterone—3.28 ± 3.51, 2.13 ± 1.94,
5.52 ± 4.13 and 3.88 ± 3.12 pg/ml, respectively; D-dimer
serum level was 0.69 ± 2.42 lg/ml; the fibrinogen level
was 245.12 ± 67.03 mg/dl, respectively; APTT—30.81 ±
3.03 s and PT—12.00 ± 0.90 s.
On the other hand, in the control group (II) the bio-
chemical and laboratory results were as follows (Table 2):
mean serum estradiol—214.81 ± 256.76 pg/ml, in the
follicular phase—245.00 ± 251.70 pg/ml, in the ovulation
peak—67.05 ± 15.28 pg/ml and in the luteal phase—
202.70 ± 282.92 pg/ml; mean blood progesterone—
1.34 ± 1.27, 1.24 ± 1.10, 0.86 ± 0.33 and 1.57 ±
1.56 pg/ml, respectively; D-dimer serum level was 0.36 ±
0.45 lg/ml; the fibrinogen level was 238.68 ± 54.48
mg/dl, respectively; APTT—29.78 ± 2.10 s and PT—
12.06 ± 0.63 s.
A statistical dependence was observed in the differences
in estradiol level in the follicular phase and ovulation peak
(p = 0.020 and p = 0.010) as well as for progesterone in
the ovulation peak and the luteal phase (p = 0.038 and
p = 0.032) between the study and control groups.
Discussion
The causes of vertigo are relatively well-researched thanks
to highly specialised diagnostic tests. However, for a large
group of patients the tests performed so far have not shown
any abnormalities, thus making it impossible to indicate a
direct cause for the vertigo [13].
In the literature, the most common background is vascular
(50–70 %), viral (12–25 %) and autoimmunological (18 %).
The combined contraceptive pill has been available in
pharmacies for more than 50 years. Owing to its high
effectiveness (Pearl index approx. 0.5 %), full reversibility
of its effects and high acceptability by women, it has
become the most universal contraceptive method [14].
Currently, it is estimated that approx. 100 million women
take the combined contraceptive pill.
Giacomini et al. [15] believe that in patients taking oral
contraceptives, the direct cause of suffering from mild
paroxysmal vertigo is a disturbed electrolyte balance,
changes in endolymph pH, and disturbed metabolism of
glucose and lipids resulting from the use of hormonal
contraceptives, confirmed by the authors’ own studies.
According to Mitre et al. [16] the use of hormonal
contraceptives may contribute to the occurrence of tinnitus
or disorders of the vestibular system. No negative impact
on hearing has been observed.
A slightly moderate hearing loss according to the CPT
of 5.87 ± 16.69 % for the right year and of 3.47 ± 8.14 %
for the left year was observed in the authors’ own studies.
In the studies by Mueck et al. [17], the negative impact
of oral contraceptives on diseases of the inner ear was not
confirmed. Similar conclusions are drawn from the studies
of Vessey et al. [6], who also believe that drugs containing
less than 50 lg of the oestrogen component have a lower
impact on thromboembolic episodes.
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Lu et al. [18] concluded that in patients with sudden
deafness, the levels of total cholesterol, triglycerides and
lipoproteins were significantly higher compared to the
control group. This may be an additional factor influencing
blood viscosity, decreasing the blood supply to the cochlea.
In another report, Lu et al. [19] proved that in patients
with sudden deafness, the level of fibrinogen and viscosity
of the blood plasma were significantly higher compared to
the control group. This may promote thrombophilia and
decrease the blood supply to the cochlea.
The serum level of estradiol and progesterone depends
on the menstrual cycle. In the study group (I) the patients
were: in the follicular phase in 43.1 % of cases, in the
ovulation peak in 11.8 % of cases, and in the luteal phase
in 45.1 % of cases, whereas in the control group (II) in
52.8, 7.5 and 39.6 % of cases, respectively.
The authors’ own studies found that the estradiol level in
the blood serum, considering the menstrual cycle phase in
the study group (I) was as follows: below normal in 11.8 %
of the patients, normal in 58.8 % of the patients and above
normal in 29.4 % of the patients, whereas in the control
group (II) in 35.8 % of the patients, in 52.8 % of the
patients and in 11.3 % of the patients, respectively.
An analysis of the progesterone level in the blood
serum, considering the menstrual cycle phase in the study
group (I), gave the following values: below normal in
23.5 % of the patients, normal in 49.0 % of the patients and
above normal in 27.5 % of the patients, whereas in the
control group (II) in 35.8 % of the patients, in 52.9 % of
the patients and in 11.3 % of the patients, respectively.
The studies by Vliet et al. [20] show that a greater
oestrogen level in hormonal contraceptives contributes to
an increased level of sex hormone-binding proteins
(SHBPs). The impact of contraceptives on the increased
level of SHBPs may be a risk indicator for a thromboem-
bolic event.
Sitruk-Ware [21] states that there are great differences
between individual progesterone components used in con-
traceptives, and that the final effect of a progesterone
component depends on the type and dose of the combined
oestrogen.
It has been shown that oral contraceptives influence the
level of almost every protein of the blood coagulation
system [10, 22].
Considering the delicate balance between the coexisting
components of the coagulation and fibrinolytic system,
even the slightest variation in the level of proteins partic-
ipating in the coagulation process may launch a cascade. In
the performed studies, it has been proven numerous times
that oral contraceptives, depending on the generation and
progesterone component, increase the level of fibrinogen,
prothrombin, and coagulation factors VII, VIII and X,
while decreasing the level of factor V, antithrombin, and
the concentration and activity of the tissue factor pathway
inhibitor (TFPI) [11, 23, 24]. Moreover, it has been proven
that taking third-generation oral contraceptives is associ-
ated with a greater risk of thromboembolic disease than
using older, second-generation drugs.
In the authors’ own studies, the D-dimer level in the
blood serum in the study group (I) was as follows: normal
in 80.8 % of the patients and above normal in 19.2 % of
the patients, whereas in the control group (II) in 81.1 % of
the patients and in 18.9 % of the patients, respectively.
The evaluated fibrinogen level in the blood serum in the
study group (I) was as follows: below normal in 19.2 % of
the patients and normal in 80.8 % of the patients, whereas
in the control group (II) in 26.4 % of the patients and in
73.6 % of the patients, respectively. The prothrombin time
(s) tested in the study group (I) was as follows: below
normal in 86.5 % of the patients and normal in 13.5 % of
the patients, whereas in the control group (II) in 94.3 % of
the patients and in 5.7 % of the patients, respectively. The
tested APTT coagulation time was normal in all women in
the study and control groups.
As shown in the available publications, oral contracep-
tives increase the risk of thromboembolic episodes mani-
festing as an ischemic stroke or myocardial infarction,
while the main factor responsible for the formation of
thrombi is the oestrogen component level in the pill.
Recent publications have been describing an oestrogen/
progesterone complex increasing the risk of thrombi and
embolisms [11, 24]. In their own studies the authors
observed an abnormal estradiol level in the serum of 51 %
of the patients, which may be a reason for the activation of
the coagulation cascade.
Tanis et al. [25] emphasise the increased risk of
thromboembolic disease during the use of contraceptives in
patients who smoke, have hypertension, diabetes or
hypercholesterolemia.
In his report, Stenchever [26] states that the prevalence
of thromboembolic disease is related to the dose of
oestrogen.
Contraceptives that have a smaller dose of oestrogens
(20 lg) pose a lower risk of thromboembolic disease, as
indicated by Lidegaard et al. [27].
Conclusions
1. The vertigo occurring in the study group was most often
central (59.6 % of cases), mixed with compensation in
36.6 % of cases, and peripheral only in 3.8 % of cases,
indicating labyrinth damage in 40.4 % of cases.
2. In their own studies, the authors observed that the
plasma estradiol, considering the menstrual cycle
phase in the study group, was abnormal in 41.2 % of
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the patients and that differences in its concentration
were statistically significant in the study and control
groups (p = 0.005), which may have a negative
impact on the possibility of a thromboembolic episode.
3. An analysis of the progesterone level, considering the
menstrual cycle phase in the group, showed that its
value was abnormal in 51.0 % of patients in the study
group and 47.1 % in the control group.
4. A statistical dependence was observed in the differ-
ence of estradiol level in the follicular phase and
ovulation peak (p = 0.020 and p = 0.010) as well as
for progesterone in the ovulation peak and the luteal
phase (p = 0.038 and p = 0.032) between the study
and control groups.
5. The analysed biochemical parameters related to blood
coagulation, such as: D-dimer level, fibrinogen and
prothrombin time, were found to be abnormal in the
study group in 19.2, 19.2 and 86.5 % of cases,
respectively, whereas in the control group in 18.95,
26.4 and 94.3 % of cases, respectively.
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